Institutional investors are returning to psychedelic medicine in force, with the sector raising more than US$1 billion in a single...

For much of the past decade, Australia's medicinal cannabis industry has been defined by domestic growth. Companies raced to expand...

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early...

In 1962, an American chemist quietly created an experimental compound in a laboratory at Parke, Davis & Company. It was...

Newly rebranded BLS Pharmaceuticals (ASX:BLS) has capped off a transformational financial year, reporting record revenue, profitability and operating cash flow...

LSD has moved a significant step closer to becoming an approved prescription medicine after Definium Therapeutics reported positive topline results...

When Eli Lilly agreed to acquire Atai Beckley in a deal worth up to US$3.8 billion, it wasn't simply the...

BLS Pharmaceuticals (ASX: BLS) has signed a referral agreement with US-based Cayman Chemical Company, expanding its international commercial network for...

While psilocybin and MDMA have dominated the modern psychedelic renaissance, another compound has quietly remained on the sidelines. Ibogaine has...

Medicinal cannabis and psychedelic medicine are often discussed as part of the same healthcare revolution. Both involve substances that spent...